Escalon Medical Corp (ESMC) Stock Price & Analysis
Escalon Medical Corp (ESMC) fell 4.76% to USD 0.2 as of June 10, 2026 at 08:49 UTC, according to Nexqual real-time market data.
ESMC last closed at USD 0.21; the session ranged USD 0.2–0.21 on volume of 16,894 shares. Market capitalization is $1.48M, with a 52-week range of USD 0.1–0.42 (OQB). Source: Nexqual, June 10, 2026 at 08:49 UTC.
Key Statistics (as of June 10, 2026 at 08:49 UTC)
| Price | USD 0.2 |
|---|---|
| Change | ▼ 4.76% (down) |
| Previous Close | USD 0.21 |
| Open | USD 0.21 |
| Day Range | USD 0.2 – 0.21 |
| 52-Week Range | USD 0.1 – 0.42 |
| Volume | 16,894 shares |
| Market Cap | $1.48M |
| Exchange | OQB |
Technical Analysis (ESMC)
Nexqual's technical model rates ESMC "NEUTRAL" based on 2 bullish and 3 bearish signals across 123 daily candles, as of June 10, 2026 at 08:49 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 45.16 (neutral) |
| vs SMA50 | Above (USD 0.19) |
| MACD | 0 (positive) |
Analyst Ratings (ESMC)
Wall Street analysts rate ESMC "None", per Nexqual as of June 10, 2026 at 08:49 UTC.
| Consensus Rating | None |
|---|
Earnings (ESMC)
Source: Nexqual, June 10, 2026 at 08:49 UTC.
Financials & Fundamentals (ESMC)
| Total Revenue | $11.45M |
|---|---|
| Revenue Growth (YoY) | -24.90% |
| Gross Margin | +41.48% |
| Operating Margin | -16.07% |
| Profit Margin | +16.18% |
| ROE | +57.49% |
| Debt / Equity | 24.37 |
| Current Ratio | 2.59 |
| Total Cash | $3.34M |
| Total Debt | $1.01M |
| Free Cash Flow | $3.32M |
Source: Nexqual, June 10, 2026 at 08:49 UTC.
Financial Health Score (ESMC)
Nexqual rates Escalon Medical Corp's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 08:49 UTC.
| Growth | Critical — Revenue -25% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $3M cash vs $1M debt, net cash position |
| Cash Flow | Solid — FCF $3M, 12% margin |
| Efficiency | Strong — ROE 57%, ROA -8.8% |
Ownership (ESMC)
| Insider Ownership | +1.90% |
|---|---|
| Institutional Ownership | +7.91% |
| Shares Outstanding | 7.42M |
| Float | 7.27M |
| Short % of Float | +0.03% |
Source: Nexqual, June 10, 2026 at 08:49 UTC.
Leadership (ESMC)
Escalon Medical Corp is led by Richard J. DePiano (age 59), President, CEO, General Counsel & Chairman of Board, per Nexqual as of June 10, 2026 at 08:49 UTC.
| President, CEO, General Counsel & Chairman of Board | Richard J. DePiano (age 59) |
|---|---|
| COO and Principal Financial & Accounting Officer | Mark G. Wallace (age 55) |
From Escalon Medical Corp's Latest SEC 10-K Filing (filed 2025-09-29)
Key Strengths & Strategy (as disclosed to the SEC)
- The FDA and comparable agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the manufacturing and marketing of pharmaceutical and medical device equipment and related disposables, including the obligation to adhere to the FDA's Good Manufacturing Practice regulations.
- The Company's products employ proprietary technology, and this technology may infringe on the intellectual property rights of third parties. 9 The Company holds several United States and foreign patents for the Company's products.
Partnerships
- Under a non-exclusive distribution agreement with AirGas, Inc. (AirGas"), the Company distributes packages of AirGas gases in canisters containing up to 25 grams of gas.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IRIX | IRIDEX Corporation | USD 1.12 | ▲ 2.75% |
| ULGX | Urologix, Inc. | USD 0 | ▲ 0% |
| LWAY | Lifeway Foods, Inc. | USD 23.81 | ▲ 0.89% |
| FOCL | EDAP TMS S.A. | USD 4.52 | ▼ 0.88% |
| FONR | Fonar Corporation | USD 19.09 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:49 UTC. This page is informational and not investment advice.